AUTOLUS THERAPEUTICS PLC Stock Price, News & Analysis

Autolus Therapeutics plc (Nasdaq: AUTL) reported its financial results for Q4 and full-year 2021 on March 10, 2022. The company secured a $150M collaboration with Blackstone Life Sciences, with potential additional milestone payments of $100M. Notable clinical data from its obe-cel therapy displays a favorable safety profile. Autolus has cash reserves of $310.3M, extending its financial runway into 2024, despite a net loss of $142.1M for the year, a slight improvement over 2020. Key clinical milestones are anticipated in 2022 for therapies targeting various cancers.

Autolus Therapeutics (Nasdaq: AUTL) announced a publication in BioTechniques detailing a novel technology for controlled expression of gene modules, crucial in T cell therapy for cancer treatment. This method allows for very low expression levels of toxic genes, enhancing safety while maintaining efficacy. By utilizing a translational readthrough mechanism, the technology improves CAR T cell therapies targeting solid tumors, specifically allowing controlled IL-12 release without systemic toxicity. This innovation aims to maximize anti-tumor activity while minimizing risks to patients.

Autolus Therapeutics plc (Nasdaq: AUTL) will announce its fourth quarter and full year 2021 financial results and operational highlights on March 10, 2022, before U.S. market open. The management team will host a conference call at 8:30 am ET to discuss the results and provide a business update. Interested parties can access the call via webcast, with a replay available for one week afterward. This event marks a critical opportunity for investors to evaluate the company’s performance in the clinical-stage biopharmaceutical sector focused on T cell therapies.

Engitix has successfully closed a $54m Series A financing round, co-led by Netherton Investments and new investor Dompé farmaceutici S.P.A. The collaboration with Dompé includes a multi-year strategic partnership to advance Engitix's drug discovery efforts in fibrosis and cancer. Dompé will provide access to its AI-driven Exscalate platform while Engitix retains control over its assets. The funding will enhance Engitix's internal pipeline and expand its operations significantly.

Autolus Therapeutics plc (Nasdaq: AUTL) announces the retirement of CFO Andrew J. Oakley on March 31, 2022, transitioning to a non-executive director role while remaining an advisor until March 2023. Dr. Lucinda Crabtree, currently SVP of Finance, will succeed him. Oakley highlighted the company's strong financial position following a deal with Blackstone Life Sciences, allowing for strategic advancement of its lead candidate, obe-cel. Crabtree brings extensive financial experience and previously oversaw major public offerings for Autolus.

Autolus Therapeutics (AUTL) announces its 2022 corporate priorities, emphasizing the pivotal developments of its candidate obe-cel for adult ALL patients. The Phase 2 FELIX study anticipates data mid-2022, with patient recruitment ongoing. Management highlights the favorable safety profile from the Phase 1b portion of the trial, with no severe cytokine release syndrome noted. Additionally, financial backing of up to $250 million from Blackstone Life Sciences will aid in advancing therapeutic initiatives, including its new manufacturing facility in the UK to enhance production capabilities.

Autolus Therapeutics (Nasdaq: AUTL) announced its participation in two upcoming virtual conferences: the H.C. Wainwright BioConnect Conference on January 10, 2022, featuring Dr. Lucinda Crabtree, and the J.P. Morgan Healthcare Conference on January 12, 2022, with Dr. Christian Itin presenting. Both events will include investor meetings and will be accessible via Autolus' website, where an archived replay will be available for 90 days. Autolus is known for developing next-generation T cell therapies targeting cancer.

Autolus Therapeutics (AUTL) provided updates on its CAR T therapy, obe-cel, at the ASH 2021 Annual Meeting. The ALLCAR19 study reported a morphological event-free survival (EFS) of 46% at 24 months. Obe-cel achieved a metabolic complete response in 100% of patients with follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma, showing favorable safety with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported. The company anticipates further clinical data in 2022.

Autolus Therapeutics (Nasdaq: AUTL) will hold a conference call on December 13, 2021, at 8:00 am ET to discuss data presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14. This call reflects a timing change from the previous announcement. The call will include a webcast with accompanying slides available on the company's website. A replay of the call will be accessible for one week after.